Rituxan (rituximab) plus methotrexate, procarbazine and vincristine (R-MPV) plus Imbruvica (ibrutinib; R-MPV/i) induction remedy confirmed a excessive full response fee (CR) fee and was proven to be tolerable in sufferers with newly recognized main central nervous system (CNS) lymphoma (PCNSL), assembly the first and key secondary finish factors of a part 2 trial.
Information was introduced on the 2025 SNO Annual Assembly.
At a median follow-up of 32.1 months, the general response fee (ORR) was 100%, together with a CR fee of 90% (27 sufferers) and an unconfirmed CR fee of seven% (2 sufferers), translating to an general CR fee of 97% (29 sufferers). Moreover, the partial response fee was 3% (1 affected person). No sufferers had refractory illness, and the median time to finest response was 110 days.
The median progression-free survival (PFS) and general survival (OS) weren’t reached. In whole, 4 sufferers progressed with a median time to development of 15.2 months. The 2-year PFS fee was 84.2%, and the three-year PFS fee was 78.6%.
“The CR fee and the two-year PFS [rate] had been significantly better than what you’d anticipate, no matter our consolidation measurement,” lead research creator Dr. Christian Grommes, mentioned within the presentation. “The query [you] would possibly ask is: Is the addition of Imbruvica doubtlessly modulating consolidation to a much less aggressive method?” Grommes is a neuro-oncologist at Memorial Sloan Kettering Most cancers Heart in New York, New York.
Glossary:
Full response fee (CR): proportion of sufferers whose most cancers utterly disappears with therapy.
General response fee (ORR): proportion of sufferers whose most cancers shrinks or disappears after therapy.
Development-free survival (PFS): time sufferers reside with out their most cancers rising or spreading.
General survival (OS): time from therapy begin or analysis till dying from any trigger.
ECOG efficiency rating: scale that describes a affected person’s means to hold out each day actions, starting from totally lively to completely disabled.
What’s the rationale for investigating R-MPV plus Imbruvica in newly recognized PCNSL?
PCNSL is an aggressive type of non-Hodgkin lymphoma that develops within the CNS. Roughly 90% of instances of PCNSL current as diffuse massive B-cell lymphoma. Recurrent B-cell receptor signaling axis mutations in genes like MYD88 and CD79B are frequent on this illness and might be focused, in line with Grommes.
Methotrexate (MTX)/R-MPV is a standard induction routine used to deal with sufferers with newly recognized PCNSL. Grommes defined that beforehand, a potential trial carried out at Memorial Sloan Kettering Most cancers Heart confirmed that induction remedy with R-MPV generated a 66% CR fee, a median PFS of three.3 years, and a two-year PFS fee of 78% on this affected person inhabitants. Moreover, the multicenter part 2 NRG1114 trial demonstrated a CR fee of 76% and a two-year PFS fee of 54% with R-MPV plus cytarabine on this affected person inhabitants.
Moreover, a part 2 trial confirmed a 74% ORR with Imbruvica monotherapy in sufferers with recurrent PCNSL.Collectively, these knowledge supported the rationale for evaluating Imbruvica plus R-MPV in sufferers with newly recognized PCNSL.
“The concept that we had was to maneuver…brokers which are profitable within the recurrent, refractory setting in lowering tumor measurement into the up-front [setting],” Grommes defined.
What was the security profile of R-MPV/i in sufferers with PCNSL?
The commonest any-grade unwanted side effects had been decreased platelet counts (30 sufferers), lymphopenia (29 sufferers), anemia (28 sufferers), elevated alanine aminotransferase (ALT) ranges (28 sufferers), and elevated aspartate aminotransferase (AST) ranges (28 sufferers). The commonest grade 3 (extreme) unwanted side effects had been lymphopenia (19 sufferers), anemia (16 sufferers), decreased white blood cell (WBC) counts (13 sufferers), decreased neutrophil counts (9 sufferers), elevated ALT ranges (9 sufferers), decreased platelet counts (4 sufferers), elevated AST ranges (3 sufferers), and elevated creatine ranges (1 affected person).
No grade 5 (dying) unwanted side effects had been reported. Grade 4 (life-threatening) toxicities included neutropenia (4 sufferers), lymphopenia (3 sufferers), thrombocytopenia (3 sufferers), and decreased WBC counts (3 sufferers). Though Grommes famous that cardiotoxicity is a priority with the usage of Imbruvica, on this trial, solely two sufferers developed atrial fibrillation, and just one affected person developed deep venous thrombosis. Investigators reported no main hemorrhage or Aspergillus/Pneumocystis infections.
“The mix of R-MPV plus Imbruvica is a superb mixture with glorious chance, particularly no fungal infections, no main cardiac issues, and no hemorrhagic [side effects],” Grommes concluded.
What was the design of the part 2 trial evaluating R-MPV/i in sufferers with newly recognized PCNSL?
This trial enrolled sufferers no less than 18 years of age with newly recognized PCNSL who had an ECOG efficiency rating of two or decrease and regular end-organ perform. Sufferers who had acquired 1 to 2 prior doses of methotrexate had been allowed to enroll.
Sufferers had been handled over 4 28-day cycles with:
- Rituxan at 500 milligrams per sq. meter (mg/m2) on days 0+ to 14
- MTX on 3.5 g/m2 on days 1+ to fifteen
- Vincristine at 1.4 mg/m2 on days 1+ to fifteen of cycles 1 and a pair of
- Procarbazine at 100 mg/m2 on days 1 to 7 of every cycle
- Imbruvica at 560 mg on days 5 to 14 and 19 to twenty-eight of every cycle
Consolidation therapy was decided by the investigators.
The first finish level was general CR fee at finish of induction. Secondary finish factors included security and tolerability, PFS and OS.
References
- “Imbruvica together with Rituxan, methotrexate, vincristine, and procarbazine for newly recognized main CNS lymphoma” by Dr. Schaff, et al., introduced on the 2025 SNO Annual Assembly.
- “MTX-based chemotherapy mixed with low-dose whole-brain radiotherapy improves progression-free survival for sufferers with newly recognized CNS lymphoma” by NRG Oncology, information launch.
- “A part 2 research assessing long-term response to Imbruvica monotherapy in recurrent or refractory CNS lymphoma” by Dr. Grommes, et al., Scientific Most cancers Analysis.
For extra information on most cancers updates, analysis and training, don’t overlook to
